Jago Grahak Jago

Jago Grahak Jago Logo

July 2023

New Import Regulations introduced in Gambia for Drugs – Pre Shipment Inspections – Product Testing related

The Medicines Control Agency (MCA), The Gambia has introduced the regulation of pre- shipment document verification, physical inspection, quality control testing and issuance of Clean Report of Inspection and Analysis (CRIA) for Pharmaceuticals to address issues related to substandard and falsified (counterfeit) medicines entering the country. This regulation requires all imported pharmaceutical products from India […]

New Import Regulations introduced in Gambia for Drugs – Pre Shipment Inspections – Product Testing related Read More »

Spices from India recalled; FDA issues import detention notice

The FDA has analyzed samples of three products, Everest Garam Masala, Everest Sambhar Masala, and Maggi Masala ae Magic, and the results showed the products were contaminated with Salmonella.  The products were manufactured in India and are not labeled for distribution in the United States. All three products were imported to the United States and

Spices from India recalled; FDA issues import detention notice Read More »

US telemedicine platform ‘Drs.OnCalls’ enters India to offer consultation with doctors globally 24×7

Drs.OnCalls, a leading telemedicine platform based in the United States, has announced its strategic expansion into the Indian market. Having successfully established its presence in multiple countries, Drs.OnCalls brings a wealth of expertise and experience to India’s growing telemedicine sector. The company is committed to providing convenient, accessible, and high-quality healthcare services to individuals across

US telemedicine platform ‘Drs.OnCalls’ enters India to offer consultation with doctors globally 24×7 Read More »

South India’s premier pharma expo ‘Pharmac South’ to be held at Chennai Trade Centre on July 14 and 15

The pharma B2B event hosted by the Indian Drug Manufacturers’ Association Tamil Nadu chapter (TN IDMA) every year in Chennai will be held at the Chennai Trade Centre on July 14 and 15 this year with participation of a wide range of stakeholders of the sector. The business to business event ‘Pharmac South’ is the

South India’s premier pharma expo ‘Pharmac South’ to be held at Chennai Trade Centre on July 14 and 15 Read More »

DCGI in talks with global consultants to rationalise drug regulations to ensure quality

In order to achieve quality, compliance and patient safety, the Central Drugs Standard Control Organisation (CDSCO) is rationalising the drug regulations in consultation with global regulatory experts. This, according to the Drugs Controller General of India (DCGI) Rajeev Singh Raghuvanshi, will be done towards ease of doing business and developing a quality culture. Speaking on

DCGI in talks with global consultants to rationalise drug regulations to ensure quality Read More »

Indian pharma industry to reach $57 billion by FY 25: CareEdge Ratings report

The Indian pharmaceutical industry is expected to grow at 7-8 per cent in FY24 to FY25 with prospects to reach $57 billion by FY25, after registering a Compound Annual Growth Rate of 6-8 per cent during FY18 to FY23, according to CareEdge Ratings. In a latest report, the knowledge-based analytical group said that the Indian

Indian pharma industry to reach $57 billion by FY 25: CareEdge Ratings report Read More »

SaSPinjara sees Indian pharma needs ample guidance for China market entry going by regulatory approval challenges

SaSPinjara Life Sciences, the technical and business consultation provider for the pharma business in the global market, now sees that for Indian companies, China regulation is still very complex. Only companies with experience in the Chinese market have a certain advantage. It will take at least five years from the establishment of a joint venture

SaSPinjara sees Indian pharma needs ample guidance for China market entry going by regulatory approval challenges Read More »

USP sets up a programme unit team on excipients with a mandate for fiscal 2024 on specific areas of DEG and EG

The United States Pharmacopoeia (USP) has set up a programme unit team on excipients with a mandate for fiscal 2024 on the specific areas of di-ethylene glycol (DEG) and ethylene glycol (EG). The plan envisages contributing in testing excipients and also helping enhance criticality of testing methods in collaborations with USP headquarters in the US.

USP sets up a programme unit team on excipients with a mandate for fiscal 2024 on specific areas of DEG and EG Read More »

Delhi HC refuses to grant interim injunction in favour of Bayer Healthcare in patent dispute over regorafenib

The Delhi High Court has refused to grant interim injunction in favour of Bayer Healthcare LLC in a patent litigation against Natco Pharma and MSN Laboratories in which the former has sought interim injunction against the two Indian companies from infringing the patent rights of its anti-cancer drug regorafenib, branded in India as Nublexa and

Delhi HC refuses to grant interim injunction in favour of Bayer Healthcare in patent dispute over regorafenib Read More »